Cargando…
Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib
With the rapid development and adoption of novel anti-cancer therapeutics, physicians commonly encounter cancer patients on regimens with recently approved drugs for which information about rare or long-term side effects may not be available. In this case, we present a young woman with cholangiocarc...
Autores principales: | Papaila, Alexa, Jacobson, Alexis T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255035/ https://www.ncbi.nlm.nih.gov/pubmed/34258110 http://dx.doi.org/10.7759/cureus.15441 |
Ejemplares similares
-
A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Lopina, Nataliia, et al.
Publicado: (2022) -
Genetic Evaluation of Late-Onset Hypertrophic Cardiomyopathy: An Autobiographical Case Report
por: Carlo, Simon, et al.
Publicado: (2022) -
A Rare Cause of Infantile-Onset Cardiomyopathy With Ocular Manifestations: Alström Syndrome
por: Snobar, Rania, et al.
Publicado: (2022) -
Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022) -
New-Onset Heart Failure From Viral Myocarditis and Inflammatory Cardiomyopathy: A Case Report
por: Singh, Bir P, et al.
Publicado: (2022)